Annals of Surgical Oncology

, Volume 26, Issue 3, pp 836–844 | Cite as

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer

  • Yasuo Uno
  • Mitsuro KandaEmail author
  • Takashi Miwa
  • Shinichi Umeda
  • Haruyoshi Tanaka
  • Chie Tanaka
  • Daisuke Kobayashi
  • Masaya Suenaga
  • Norifumi Hattori
  • Masamichi Hayashi
  • Suguru Yamada
  • Goro Nakayama
  • Michitaka Fujiwara
  • Yasuhiro Kodera
Gastrointestinal Oncology



Identification of gastric cancer-related molecules is necessary to elucidate the pathological mechanisms of this heterogeneous disease. The purpose of this study was to identify novel genes associated with aggressive phenotypes of gastric cancer.


Global expression profiling was conducted using tissues from four patients with metastatic gastric cancer to identify genes overexpressed in gastric cancer. Fifteen gastric cell lines and 262 pairs of surgically resected gastric tissues were subjected to mRNA expression analysis. The contribution of the candidate gene on gastric cancer cell proliferation, invasion, adhesion, and migration were evaluated using small interfering RNA.


DnaJ heat shock protein family (Hsp40) member C12 (DNAJC12) was identified as a candidate gene by transcriptome analysis. In clinical samples, DNAJC12 mRNA levels were higher in gastric cancer tissues compared with normal adjacent tissues. Patients with high DNAJC12 expression showed significantly shorter overall survival in our cohort and in the extra-validation cohort analyzed by a published microarray dataset. High DNAJC12 expression in gastric cancer tissues was significantly associated with lymphatic involvement, infiltrative growth type, lymph node metastasis, and advanced stage and was identified as an independent prognostic factor for overall survival in multivariable analysis. Increased expression of DNAJC12 was found in 12 of 14 examined gastric cancer cell lines. Knockdown of DNAJC12 expression significantly decreased the proliferation and invasion abilities of gastric cancer cells.


Our findings support DNAJC12 as a candidate gene associated with aggressive phenotypes of gastric cancer.




Supplementary material

10434_2018_7149_MOESM1_ESM.doc (44 kb)
Supplementary material 1 (DOC 43 kb)
10434_2018_7149_MOESM2_ESM.docx (21 kb)
Supplementary material 2 (DOCX 21 kb)
10434_2018_7149_MOESM3_ESM.doc (52 kb)
Supplementary material 3 (DOC 51 kb)
10434_2018_7149_MOESM4_ESM.tif (5.9 mb)
Supplementary Fig. 1 (a) Expression analyses of DNAJC12 in clinical samples from 262 gastric cancer patients. ROC curve analysis revealed that the AUC value of DNAJC12 levels was 0.606 for detection of mortality of recurrence, and the optimal cutoff value was 0.00925. (b) Expression analysis of DNAJC12 in gastric cancer cell lines. DNAJC12 mRNA levels were detected in differentiated and undifferentiated gastric cancer cell lines and the control FHs74 epithelial cell line (TIFF 6033 kb)


  1. 1.
    Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–64.CrossRefGoogle Scholar
  2. 2.
    Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015;9:1549–60.CrossRefGoogle Scholar
  3. 3.
    Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–55.CrossRefGoogle Scholar
  4. 4.
    McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11:664–74.CrossRefGoogle Scholar
  5. 5.
    Kanda M, Kodera Y. Recent advances in the molecular diagnostics of gastric cancer. World J Gastroenterol. 2015;21:9838–52.CrossRefGoogle Scholar
  6. 6.
    Duraes C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464:367–78.CrossRefGoogle Scholar
  7. 7.
    Shevtsov M, Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. Front Immunol. 2016;7:171.Google Scholar
  8. 8.
    Straniero L, Guella I, Cilia R, et al. DNAJC12 and dopa-responsive nonprogressive parkinsonism. Ann Neurol. 2017;82:640–6.CrossRefGoogle Scholar
  9. 9.
    Kanda M, Shimizu D, Tanaka H, et al. Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer. Oncotarget. 2016;7:13667–79.CrossRefGoogle Scholar
  10. 10.
    Kanda M, Nomoto S, Oya H, et al. The expression of melanoma-associated antigen d2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression. Ann Surg Oncol. 2016;23 Suppl 2:214–21.CrossRefGoogle Scholar
  11. 11.
    Liu JY, Peng CW, Yang XJ, Huang CQ, Li Y. The prognosis role of AJCC/UICC 8(th) edition staging system in gastric cancer, a retrospective analysis. Am J Transl Res. 2018;10:292–303.Google Scholar
  12. 12.
    Kanda M, Murotani K, Kobayashi D, et al. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: a propensity score matching analysis. Surgery. 2015;158:1573–80.CrossRefGoogle Scholar
  13. 13.
    Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol. 2014;20:13718–27.CrossRefGoogle Scholar
  14. 14.
    Szasz AM, Lanczky A, Nagy A, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1065 patients. Oncotarget. 2016;7:49322–33.CrossRefGoogle Scholar
  15. 15.
    Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138:721–30.CrossRefGoogle Scholar
  16. 16.
    Kanda M, Shimizu D, Tanaka H, et al. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric cancer. Ann Surg. 2018;267:495–503.CrossRefGoogle Scholar
  17. 17.
    Shimizu D, Kanda M, Tanaka H, et al. GPR155 serves as a predictive biomarker for hematogenous metastasis in patients with gastric cancer. Sci Rep. 2017;7:42089.CrossRefGoogle Scholar
  18. 18.
    Kanda M, Tanaka C, Kobayashi D, et al. Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer. Int J Cancer. 2016;139:2290–8.CrossRefGoogle Scholar
  19. 19.
    Miwa T, Kanda M, Tanaka H, et al. FBXO50 enhances the malignant behavior of gastric cancer cells. Ann Surg Oncol. 2017;24:3771–9.CrossRefGoogle Scholar
  20. 20.
    Matz JM, Blake MJ, Tatelman HM, Lavoi KP, Holbrook NJ. Characterization and regulation of cold-induced heat shock protein expression in mouse brown adipose tissue. Am J Physiol. 1995;269:R38–47.Google Scholar
  21. 21.
    Ikwegbue PC, Masamba P, Oyinloye BE, Kappo AP. Roles of heat shock proteins in apoptosis, oxidative stress, human inflammatory diseases, and cancer. Pharmaceuticals (Basel). 2018;11:2.CrossRefGoogle Scholar
  22. 22.
    Laplante AF, Moulin V, Auger FA, et al. Expression of heat shock proteins in mouse skin during wound healing. J Histochem Cytochem. 1998;46:1291–301.CrossRefGoogle Scholar
  23. 23.
    Johnston CL, Marzano NR, van Oijen AM, Ecroyd H. Using single-molecule approaches to understand the molecular mechanisms of heat-shock protein chaperone function. J Mol Biol. 2018;430:4525–46.CrossRefGoogle Scholar
  24. 24.
    Tsan MF, Gao B. Heat shock protein and innate immunity. Cell Mol Immunol. 2004;1:274–9.Google Scholar
  25. 25.
    Chen B, Feder ME, Kang L. Evolution of heat-shock protein expression underlying adaptive responses to environmental stress. Mol Ecol. 2018;27:3040–54.CrossRefGoogle Scholar
  26. 26.
    Haug M, Schepp CP, Kalbacher H, Dannecker GE, Holzer U. 70-kDa heat shock proteins: specific interactions with HLA-DR molecules and their peptide fragments. Eur J Immunol. 2007;37:1053–63.CrossRefGoogle Scholar
  27. 27.
    Lee MS, Lee J, Lee S, et al. Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget. 2018;9:7961–7974.Google Scholar
  28. 28.
    Shen H, Mu C, Wu X, et al. Chemotherapy sensitizes therapy-resistant cells to mild hyperthermia by suppressing heat shock protein 27 expression in triple negative breast cancer. Clin Cancer Res. 2018;24:4900–12.CrossRefGoogle Scholar
  29. 29.
    Blau N, Martinez A, Hoffmann GF, Thony B. DNAJC12 deficiency: a new strategy in the diagnosis of hyperphenylalaninemias. Mol Genet Metab. 2018;123:1–5.CrossRefGoogle Scholar
  30. 30.
    De Bessa SA, Salaorni S, Patrao DF, Neto MM, Brentani MM, Nagai MA. JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status. Int J Mol Med. 2006;17:363–7.Google Scholar
  31. 31.
    He HL, Lee YE, Chen HP, et al. Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Exp Mol Pathol. 2015;98:338–45.CrossRefGoogle Scholar
  32. 32.
    Choi J, Djebbar S, Fournier A, Labrie C. The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress. Cell Stress Chaperones. 2014;19:439–46.CrossRefGoogle Scholar
  33. 33.
    Wegele H, Muller L, Buchner J. Hsp70 and Hsp90: a relay team for protein folding. Rev Physiol Biochem Pharmacol. 2004;151:1–44.CrossRefGoogle Scholar
  34. 34.
    Jin H, Xie Q, Guo X, et al. p63alpha protein up-regulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wasf3/Wave3/MMP9 signaling and bladder cancer invasion. J Biol Chem. 2017;292:15952–63.CrossRefGoogle Scholar
  35. 35.
    Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000;2:469–75.CrossRefGoogle Scholar
  36. 36.
    Singh S, Suri A. Targeting the testis-specific heat-shock protein 70-2 (HSP70-2) reduces cellular growth, migration, and invasion in renal cell carcinoma cells. Tumour Biol. 2014;35:12695–706.CrossRefGoogle Scholar
  37. 37.
    Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35 Suppl:S78–103.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Yasuo Uno
    • 1
  • Mitsuro Kanda
    • 1
    Email author
  • Takashi Miwa
    • 1
  • Shinichi Umeda
    • 1
  • Haruyoshi Tanaka
    • 1
  • Chie Tanaka
    • 1
  • Daisuke Kobayashi
    • 1
  • Masaya Suenaga
    • 1
  • Norifumi Hattori
    • 1
  • Masamichi Hayashi
    • 1
  • Suguru Yamada
    • 1
  • Goro Nakayama
    • 1
  • Michitaka Fujiwara
    • 1
  • Yasuhiro Kodera
    • 1
  1. 1.Department of Gastroenterological Surgery (Surgery II)Nagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations